their products. Similarly, a USDA import ban on bovine tissues applies only if they are destined for use in food and medical products, not if they are to become dietary supplements. One nationally distributed supplement lists 17 bovine organs, including brain, as ingredients.

The United States has not imported British beef since 1985, and it banned imports of live cows from BSE-affected countries in 1989. But a recent report by a scientific advisory panel to the European Union says that tonnes of high-risk European beef products are shipped to the United States annually. They include gelatin, collagen, semen and albumin, and are used in products including cosmetics and vaccines. (In December, the FDA forbade US drug-makers to use bovine serum from BSE-affected countries in certain vaccines, but vaccines produced before the ban are still in use.)

Besides the loopholes for exports, measures to protect the US herd are sometimes disregarded. BSE is believed to have spread through the practice, now prohibited, of using cow and sheep parts in cattle feed. The FDA announced on 10 January that hundreds of US feed producers are not complying with 1997 regulations enforcing the ban.

Beyond the challenge of enforcing current regulations, the US agencies need to examine how to plug loopholes, and to determine the best way to spend limited resources fighting a dimly understood enemy. How much effort should be spent in developing a screening test for the diseases or finding a treatment, or on blocking any imported or home-grown vehicle that might spread the diseases?

Deer and elk herds in the western United States, for instance, are being afflicted in growing numbers with an analogous ailment called chronic wasting disease. Last week, the committee that extended the blood-donor ban was asked to consider if and how blood donations from people exposed to these deer and elk should be restricted. It decided there were not yet enough data to implement restrictions on them.

All of these issues "get into foreign policy questions, trade issues, regulation of hunters, which Americans hate. These are all politically tricky," says Caplan.

At the advisory committee meeting last week, scientists complained of the lack of data on which to base their decisions — including the future curve of the epidemic in Europe, and the risk of exposure in other European countries compared with the United Kingdom. "These decisions ... are really guesses," said Stanley Prusiner, who won a Nobel prize in 1997 for discovering prions and elucidating how they cause disease.

Public have right to see data from all gene trials, says FDA

Paul Smaglik, Washington

The US Food and Drug Administration (FDA) last week put forward proposals to make clinical trials in gene therapy and xenotransplantation more transparent. The move drew support from some academic scientists, but criticism from the biotechnology industry.

The proposal — which interested parties have 90 days to comment on — would close a loophole that allows some data from privately funded trials to be concealed. Comments can be sent to fdadockets@oc.fda.gov.

Public disclosure became an issue in 1999, after a teenager died in a clinical trial at the University of Pennsylvania.

Adverse effects from federally funded gene-therapy trials are meant to be reported to the National Institutes of Health (NIH) and the FDA. But after the death, NIH investigators learnt that hundreds of such events had not been reported to the agency, which makes data public through the Recombinant DNA Advisory Committee (RAC). Most had only been reported to the FDA, which keeps

them confidential. Researchers complained that the agencies had different reporting standards. Last week's announcement aims to harmonize those requirements, and expand them to xenotransplantation.

The new policy would ensure that data on adverse events from all gene-therapy trials would be made public. Some are already made public through an NIH database: the change would ensure that this database contains information from all ongoing trials.

Inder Verma, president of the American Society of Gene Therapy, applauds the FDA's proposal, describing it as necessary to regain public trust. "Anything that will make it a more open process is good," says Verma, a Salk Institute gene therapy researcher.

Michael Werner of the Biotechnology Industry Organization (BIO), which opposes the proposal, says it raises privacy concerns. The BIO favours releasing aggregated safety data and reports on trends in adverse events rather than information about individual trials.

♦ <http://www4.od.nih.gov/oba/clinicaltrial.htm>

Students fuzzy about the future

Mark Schrope

Students at US graduate schools are happy to be doing PhDs and love their research, a new survey says. But they do not get enough teacher training or career advice, and their rapport with staff has room for improvement.

Just 3% of those surveyed admitted to being unhappy with their decision to pursue a PhD and 93% said their research interested them "a great deal". But more than a third might consider changing universities, advisers or dissertation topics

if given the chance to start again.

The survey, carried out by the University of Wisconsin at Madison for the Pew Charitable Trusts, polled more than 4,000 students in the third year or above in 27 graduate programmes.

"We were trying to bring the experiences and voices of students into the debate," says lead author, educationalist Chris Golde.

Only about a third felt their programmes were preparing them to teach lecture courses, compared with three-quarters who felt up to the task of conducting research. Students in the 'hard sciences' were more likely than those in the social sciences or humanities to be required to teach, but were less likely to receive any training.

Under half had a clear understanding of what (or how long) it would take for them to graduate. Molecular biologists and chemists were the fuzziest on these points, probably reflecting the unpredictable nature of laboratory research, according to the report.

The report's authors call for better communication between staff and students, including annual reviews to discuss needs, expectations and progress — an opportunity now only available to about half the students. They also urge students to voice their needs and expectations.